By Banks Albach
Daily Journal Staff Writer
Daily Journal Staff Writer
Atlanta-based Arbor Pharmaceuticals LLC plans to buy XenoPort Inc., a Redwood City-based biopharmaceutical company with a pipeline of drugs approaching late-stage trials, for roughly $467 million. The deal was announced Monday.
Simpson Thatcher & Bartlett LLP and Alston & Bird LLP are advising Arbor and Weil, Gotshal & Manges LLP is advising XenoPort.
Arbor, focuse...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In